Clinical Trials
7 trialsNCT03765918 2026-05-12
MK-3475-689
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT03157128 2026-04-16
LIBRETTO-001
Eli Lilly and Company
Phase 1/2 Active not recruiting
NCT03899792 2026-01-06
LIBRETTO-121
Eli Lilly and Company
Phase 1/2 Active not recruiting
NCT03690388 2025-09-25
A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy
Exelixis
Phase 3 Active not recruiting
NCT02358031 2025-07-18
MK-3475-048
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT03037385 2025-05-31
ARROW
Hoffmann-La Roche
Phase 1/2 Completed
NCT02034110 2023-08-21
Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers
Novartis
Phase 2 Completed